活络效灵丹通过外泌体介导治疗气滞血瘀型肠癌耐药方面的临床观察  

Clinical Observation on the Treatment of Drug-resistant Colorectal Cancer with Qi Stagnation and Blood Stasis Type Through Exosome Mediation Using Huoluo Xiaoling Pill

作　　者：谢晓彤 李志明 吴辉渊[2] 王国娟[2] 张峰浩 XIE Xiaotong;LI Zhiming;WU Huiyuan;WANG Guojuan;ZHANG Fenghao(Jiangxi University of Chinese Medicine,Nanchang 330004,China;The Affiliated Hospital of Jiangxi University of Chinese Medicine,Nanchang 330006,China)

机构地区：[1]江西中医药大学,南昌330004 [2]江西中医药大学附属医院,南昌330006

出　　处：《江西中医药大学学报》2025年第1期51-54,共4页Journal of Jiangxi University of Chinese Medicine

基　　金：江西省中医药管理局科技计划项目(2022B933)。

摘　　要：目的:观察活络效灵丹通过外泌体介导治疗气滞血瘀型结直肠癌多药耐药患者的有效性及安全性。方法:选取2021年1月—2023年6月江西中医药大学附属医院收治的结直肠癌多药耐药患者60例,随机分为观察组和对照组,各30例。2组均采用瑞戈非尼靶向治疗,观察组在对照组基础上加用活络效灵丹治疗,21 d为1个周期,共治疗2个周期。治疗后分别观察2组患者的临床疗效、中医证候积分、实验室指标、生存质量评分以及不良反应发生率。结果:治疗后,观察组的客观有效率和疾病控制率均高于对照组(P<0.05),中医证候积分低于对照组(P<0.05),癌胚抗原、糖类抗原199低于对照组(P<0.05),生活质量评分高于对照组(P<0.05)。观察组和对照组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:活络效灵丹通过外泌体介导可以有效抑制气滞血瘀型结直肠癌多药耐药患者的病情进展,减轻临床症状,提高患者生活质量。Objective:Observation of the efficacy and safety of Huoluo Xiaoling Pill in the treatment of multidrug resistant patients with Qi stagnation and blood stasis type colorectal cancer mediated by exosomes.Methods:Sixty patients with multidrug resistant colorectal cancer admitted to the affiliated hospital of Jiangxi university of Chinese medicine from January 2021 to June 2023 were randomly divided into observation group and a control group,with 30 cases in each group.All cases were treated with targeted therapy of regorafenib,the observation group was treated with Huoluo Xiaoling Pill in addition to the control group.21 days was one cycle,with a total of 2 cycles of treatment.Observed the objective therapeutic effect,traditional Chinese medicine syndrome score,laboratory indicators,quality of life score,and adverse reactions of the two groups of patients separately.Results:The objective efficiency and disease control rate of the observation group after treatment were higher than those in the control group(P<0.05),the TCM syndrome score in the post-treatment observation group waslower than that in the control group(P<0.05),the carcinoembryonic antigen and carbohydrate antigen 199 in the post-treatment observation group were lower than those in the control group(P<0.05),and the quality of life score in the post-treatment observation group was higher than that in the control group(P<0.05),the incidence of adverse reactions between the observation group and the control group was not statistically significant(P>0.05).Conclusion:Huoluo Xiaoling Pill can effectively inhibit the progression of multidrug resistant colorectal cancer patients with Qi stagnation and blood stasis through the mediation of exosomes,alleviate clinical symptoms,and improve the quality of life of patients.

关 键 词：活络效灵丹 外泌体 结直肠癌 多药耐药 疗效 

分 类 号：R259[医药卫生—中西医结合]